Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 Februar 2022 - 12:07PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Filing
of Form 20-F with SEC
23
February 2022 07:00 GMT
Filing of Annual Report on Form 20-F with the US Securities and
Exchange Commission
AstraZeneca PLC (the Company) announced
today that, on 22 February 2022, it filed its 2021 Annual Report on
Form 20-F with the US Securities and Exchange Commission (SEC). The
document is available for viewing on the SEC website
at www.sec.gov and
also on the Company's website at www.astrazeneca.com.
The Company will send any holder of the Company's securities, upon
request, a hard copy of the Company's complete audited financial
statements free of charge. Requests may be made by writing to the
Company Secretary, AstraZeneca PLC, 1 Francis Crick
Avenue, Cambridge Biomedical Campus, Cambridge, CB2
0AA, UK.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
23 February 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
